Loading clinical trials...
Loading clinical trials...
Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir
This study examines the impact of fosamprenavir as part of an ART on virological, immunological and clinical parameters of genotype 1 HCV infection in HIV co-infected subjects. Fosamprenavir could have a direct or immune-mediated activity against HCV. If this is shown to be true, changes in HCV viral load or biological characteristics could be demonstrated.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hospital Príncipe de Asturias
Alcalá de Henares, Madrid, Spain
Hospital Gregorio Marañón
Madrid, Madrid, Spain
Hospital La Paz
Madrid, Madrid, Spain
Hospital Clínico San Carlos
Madrid, Madrid, Spain
Hospital Doce de Octubre
Madrid, Madrid, Spain
Hospital Ramón y Cajal
Madrid, Madrid, Spain
Start Date
March 1, 2011
Primary Completion Date
June 1, 2013
Completion Date
June 1, 2013
Last Updated
May 30, 2014
42
ACTUAL participants
Fosamprenavir
DRUG
Lead Sponsor
Fundacion SEIMC-GESIDA
Collaborators
NCT03820323
NCT03145753
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT01900015